411 материалов по теме, собраны автоматически из проверенных источников
Many patients with early-stage breast cancer do not consistently maintain the long-term hormone therapy prescribed after lumpectomy, a large U.S. insurance claims analysis indicates. The findings provide real-world context for treatment approaches that consider omitting radiation therapy, which typically rely on the…
AI could offer more precise breast cancer recurrence risk, study finds MedicalNewsToday
Enhertu: NICE Approval Expands NHS Breast Cancer Care Healthcare Digital
Избыточная диагностика при маммографии: пересмотр статистики снизил тревогу до 5% Правда.Ру
Гипердиагностика при маммографии может быть ниже UA.NEWS
A new analysis suggests mammograms may lead to far less breast cancer overdiagnosis than some earlier studies indicated. Researchers reexamined all eight major randomized screening trials and accounted for differences in follow-up time, screening frequency, and screening after trials ended. Their results were…
How biology is reshaping breast cancer care The Cancer Letter
How Paxalisib Is Being Studied in Treatment-Resistant Breast Cancer Cure Today
Launching a Venture Philanthropy Program to Accelerate Breast Cancer Innovations - BCRF Oncodaily
Wake Forest Researchers Identify a Protein That Helps Aggressive Breast Cancer Spread to the Brain BioBuzz
:format(jpg)/aHR0cHM6Ly94bi0tODBhaGNubGhzeGoueG4tLXAxYWkvbWVkaWEvbXVsdGltZWRpYS9tZWRpYWZpbGUvZmlsZS8yMDI1LzEyLzE4LzIwMjUxMjAyXzExNDcyNC5qcGc.jpg)
Новый маммограф в Ногинске ускорит диагностику рака молочной железы REGIONS.ru
The addition of CDK4/6 inhibitors to endocrine therapy has changed the standard of care for patients with high-risk, early-stage estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer by reducing the risk of recurrence. However, one patient subgroup continues to present a clinical dilemma. In current…
New trial aims to evaluate chemotherapy benefit for ER+/HER2- breast cancer patients News-Medical
Why Breast Cancer Clinical Trials Stop Early: Poor Accrual Remains the Leading Threat to Study Completion oncodaily.com
Giovanni Maria Iannantuono: Key Drivers of Early Termination in Breast Cancer Clinical Trials Oncodaily